2021, Number 1
<< Back Next >>
Med Int Mex 2021; 37 (1)
Hepatitis due to Epstein-Barr virus
Maradiaga-Montoya RY, Izaguirre JD, Sánchez E
Language: Spanish
References: 11
Page: 135-139
PDF size: 311.65 Kb.
ABSTRACT
Background: Viral hepatitis due to non-hepatotropic viruses are frequent, among
the causative agents are dengue, cytomegalovirus and Epstein-Barr virus, which can
cause cholestatic hepatitis.
Clinic case: A 28-year-old female patient, married, from the US, she lived in
Honduras since 6 months ago; she was admitted on 2/10/2017 for 6 days of daily,
intermittent fever, 38 to 40ºC, chills, myalgias, hyporexia, vomiting, diarrhea, and
pain in the epigastrium; during her hospital stay daily, intermittent febrile episodes
continued with jaundice. Patient was discharged five days later, still icteric, afebrile.
On 9/10/2017, generalized skin rash, dry cough, odynophagia and hypertrophic tonsils
with whitish exudate began, the symptoms lasted 4 days; patient again presented
fever and received symptomatic management, with total resolution of symptoms on
10/15/2017, with hemogram, bilirubins and normal transaminases.
Conclusions: Epstein-Barr virus infection is a frequent condition in young
people, characterized by fever, lymphadenopathy, exudate in tonsils and atypical
lymphocytosis, liver involvement occurs in 80% of cases, and with 5% of cases
with jaundice. In young patients with viral hepatitis, it should be considered a
differential diagnosis.
REFERENCES
Johannsen E, Kaye K. Esptein Barr virus. Mandell, Douglas, And Bennett’s Principles and Practice of Infectious Diseases. 7a ed. Infectología de Mendells. Philadelphia: Elservier; 2010: 1989-2005.
Medina-Ortega AP, López-Valencia D, Mosquera-Monje SL, Mora-Obando DL. Virus de Epstein-Barr y su relación con el desarrollo del cáncer. Iatreia. 2017; 30 (2): 131-145. doi. 10.17533/udea.iatreia.v30n2a03.
Sangueza M, Sandoval E. Epstein-Barr virus and skin. An Bras Dermatol 2018; 93 (6): 786-799. doi. 10.1590/ abd1806-4841.20187021.
Hernández S, Aguilar C, Lizardi J. Hepatitis por Epstein Barr: reporte de caso. Medica Sur 2005; 12 (3): 177-179.
Andrei G, Trompet E, Snoeck R. Novel therapeutics for Epstein-Barr virus. Molecules 2019; 24 (5): 997. doi. 10.3390/molecules24050997.
Barreales M, Pérez M, Meizoso T, Garrido M, et al. Infección por el virus de Epstein-Barr y hepatitis aguda colestásica. An Med Interna (Madrid) 2006; 23 (10): 483-486.
Shula S, Lamps L. Epstein-Barr virus hepatitis: a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 2018; 142 (10): 1191-1195. doi. 10.5858/ arpa.2018-0208-RA.
Ontanilla G, Praena J, Giráldez Á, Cordero E, et al. Severe acute hepatitis and cold agglutinin-related hemolytic anemia secondary to prime infection with Epstein-Barr virus. Rev Esp Enferm Dig 2017; 109 (5): 388-391. http://dx.doi. org/10.17235/reed.2017.4072/2015.
Khoo A. Acute cholestatic hepatitis induced by Epstein- Barr virus infection in an adult: a case report. J Med Case Reports 2016; 10 (1): 75. doi. 10.1186/s13256-016-0859-x.
Moniri A, et al. Acute Epstein-Barr virus hepatitis without mononucleosis syndrome: a case report. Gastroenterol Hepatol Bed Bench 2017; 10 (2): 147-149.
Viviani P, Salas C, Roque J. Falla hepática fulminante por virus Epstein Barr. Rol de los corticoides. Caso clínico. Rev Chil Pediatr 2013; 84 (3): 313-317. http://dx.doi.org/10.4067/ S0370-41062013000300010.
Full text